ETEiju Tsuchiya

Eiju Tsuchiya

*This is an algorithmically generated author record based on publicly available information.

Eiju Tsuchiya has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Toshiyuki Izumo

    From the Departments of Pathology (Drs Chinen, Izumo, Ohkura, and Tsuchiya) and Cancer Chemotherapy (Dr Kaneko), Saitama Cancer Center, Ina-machi, Japan; and the Department of Pathology, National Defense Medical College, Tokorozawa City, Japan (Dr Matsubara)

    2 shared publications
  • Atsushi Takahashi

    Department of Pathology, Fukujuji Hospital, Antituberculosis Association, 3‐1‐24 Matsuyama, Kiyose‐shi, Tokyo 204–8533

    1 shared publication
  • Hitoshi Nishimura

    Department of Chest Surgery, Saitama Cancer Center, 818 Ina‐machi, Kita‐Adachi‐gun, Saitama 362–0806

    1 shared publication
  • Katsuya Chinen

    From the Departments of Pathology (Drs Chinen, Izumo, Ohkura, and Tsuchiya) and Cancer Chemotherapy (Dr Kaneko), Saitama Cancer Center, Ina-machi, Japan; and the Department of Pathology, National Defense Medical College, Tokorozawa City, Japan (Dr Matsubara)

    1 shared publication
  • Ken Nakagawa

    Department of Respiratory Surgery, Cancer Institute Hospital, 1‐37‐1 Kami‐ikebukuro, Toshima‐ku, Tokyo 170–8455

    1 shared publication
  • Moriaki Hayashi

    Cancer Diagnosis Group of Research Division

    1 shared publication

Latest Publications

  • Open Access

    Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors

    by Yasuhito Kobayashi, Yoshio Tokuchi, Takehisa Hashimoto, Moriaki Hayashi, Hitoshi Nishimura, Yuichi Ishikawa, Ken Nakagawa, Yukitoshi Sato, Atsushi Takahashi, Eiju Tsuchiya

    The degree of malignancy of neuroendocrine lung tumors (NEs) increases in this order: from typical carcinoids (TCs) through atypical carcinoids (ACs) to large cell neuroendocrine carcinomas (LCNECs) and small cell lung carcinomas (SCLCs). However, histological classification has sometimes proved difficult. We here investigated loss of heterozygosity (LOH) using eight microsatellite markers and expression of p53, Bcl‐2 and Bax proteins using immunohistochemical methods in 57 NEs (19 TCs, 5 ACs, 14 LCNECs and 19 SCLCs), looking for objective genetic markers to distinguish between subtypes. The frequencies of LOHs on D3S1300, RBi2 and TP53, the combinations of LOH status for RBi2 and TP53, and the immunohistochemically demonstrated Bcl‐2/Bax ratios and p53‐positive rates significantly differed among histopathologically diagnosed NEs. Differentiation between TC and AC was possible with reference to LOH on D3S1300, RBi2 and TP53, and the combined LOH status on RBi2 and TP53 (i.e., both LOH(‐) versus one LOH(+)). For comparison between AC and LCNEC+SCLC, LOH on TP53 or the combination of two markers—one LOH(+) versus both LOH(+)—was applied. Furthermore, in three discordant cases of diagnoses based on histology and LOH markers, diagnoses using the latter were considered to be more probable by survival analysis. The present study indicated that assessment of LOHs using microsatellite markers could provide objective markers that can distinguish subtypes of NEs, for which histological assessment may commonly result in disagreement.


  • Open Access

    Nasal Natural Killer Cell/T-Cell Lymphoma Showing Cellular Morphology Mimicking Normal Lymphocytes

    by Katsuya Chinen, Yasuhiko Kaneko, Toshiyuki Izumo, Yasuo Ohkura, Osamu Matsubara, Eiju Tsuchiya

    We report the autopsy case of a 34-year-old Japanese man with a nasal natural killer (NK)-cell/T-cell lymphoma. The patient developed the disease at 32 years of age, and a biopsy of the nasopharynx revealed pleomorphic lymphoma cell proliferation. Radiotherapy was performed, but the patient eventually died of respiratory failure. After radiotherapy, no histologic evidence of malignancy was obtained with biopsy materials featuring lymphocytic infiltration. Autopsy studies, including in situ hybridization for Epstein-Barr virus–encoded RNA, revealed generalized infiltration of normal lymphocyte-like, UCHL-1–positive, and Epstein-Barr virus–encoded RNA–positive lymphoma cells. Monoclonal proliferation of the Epstein-Barr virus–carrying cells was verified by means of Southern blot analysis. Retrospectively, we concluded that the normal lymphocyte-like presentation of the lymphoma cells, probably influenced by radiotherapy, prevented pathologists from recognizing the lymphoma. The utility of in situ hybridization for Epstein-Barr virus–encoded RNA in identification of tumor cells is emphasized with respect to the present case.


  • Practical Utility of the Revised European‐American Classification of Lymphoid Neoplasms for Japanese Non‐Hodgkin's Lymphomas

    by Toshiyuki Izumo, Nobuo Maseki, Shigeo Mori, Eiju Tsuchiya

    A clinicopathological study of 515 non‐Hodgkin's lymphoma (NHL) cases was performed using the revised European‐American classification of lymphoid neoplasms (REAL classification) in an HTLV1‐nonendemic area of Japan. The following characteristics were revealed: 1) frequency of extranodal lymphomas was high (59%) with 79% B‐cell lymphomas in this series, while the overall ratio of B:T/NK lineage was 3.7:1; 2) the most common type was the diffuse large B‐cell lymphoma (46%), follicle center lymphomas occurred at an incidence lower (15%) than that in European and American populations, and marginal zone B‐cell lymphomas accounted for as much as 12%; 3) peripheral T‐cell lymphomas were common (19%), with the unspecified type predominant (11%), while adult T‐cell lymphomas were present at a level equivalent to that among European and American patients (1%). Clear segregation of survival curves was rated according to cell lineage and B‐cell lymphomas had a better prognosis than T/NK‐cell lymphomas. Furthermore, new subtypes in the REAL classification, such as marginal zone B‐cell and mantle cell lymphomas, exhibited distinct curves. Taken altogether, the REAL classification demonstrated advantages for assessment of Japanese NHL cases.